Wealthspire Advisors LLC Grows Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Wealthspire Advisors LLC increased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 3.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,812 shares of the medical research company’s stock after buying an additional 393 shares during the quarter. Wealthspire Advisors LLC’s holdings in Edwards Lifesciences were worth $977,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in EW. Turtle Creek Wealth Advisors LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth $34,000. Operose Advisors LLC grew its position in shares of Edwards Lifesciences by 247.0% during the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock worth $44,000 after purchasing an additional 452 shares in the last quarter. SRS Capital Advisors Inc. raised its stake in Edwards Lifesciences by 292.6% during the 3rd quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 474 shares during the period. NBC Securities Inc. purchased a new position in Edwards Lifesciences in the 3rd quarter worth approximately $52,000. Finally, ORG Partners LLC purchased a new position in Edwards Lifesciences in the 3rd quarter worth approximately $66,000. 79.46% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on EW. OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Mizuho boosted their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Wells Fargo & Company upped their target price on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a research report on Friday, April 26th. Oppenheimer lifted their target price on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. Finally, Citigroup raised their target price on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. One research analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus target price of $93.27.

Edwards Lifesciences Stock Up 0.4 %

Shares of EW stock traded up $0.31 during mid-day trading on Friday, hitting $87.73. The stock had a trading volume of 160,291 shares, compared to its average volume of 3,670,435. The firm has a market capitalization of $52.87 billion, a P/E ratio of 37.68, a price-to-earnings-growth ratio of 3.59 and a beta of 1.10. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The firm’s 50-day moving average is $90.03 and its two-hundred day moving average is $79.73.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The company had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. On average, analysts predict that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Bernard J. Zovighian bought 580 shares of the business’s stock in a transaction on Monday, May 6th. The shares were bought at an average price of $85.74 per share, for a total transaction of $49,729.20. Following the completion of the purchase, the chief executive officer now directly owns 3,268 shares of the company’s stock, valued at $280,198.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $94.89, for a total transaction of $688,426.95. Following the transaction, the chief financial officer now directly owns 19,074 shares in the company, valued at approximately $1,809,931.86. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Bernard J. Zovighian purchased 580 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was acquired at an average price of $85.74 per share, with a total value of $49,729.20. Following the completion of the purchase, the chief executive officer now owns 3,268 shares of the company’s stock, valued at approximately $280,198.32. The disclosure for this purchase can be found here. Insiders sold 231,550 shares of company stock valued at $20,384,302 over the last 90 days. Corporate insiders own 1.27% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.